Биохимический путь оксида азота в терапии легочной артериальной гипертензии и результаты исследования RESPITE
https://doi.org/10.26442/2075-082X_2018.2.72-76
Аннотация
Об авторах
А. А. ШмальцРоссия
С. В. Горбачевский
Россия
Список литературы
1. Легочная гипертензия. Под ред. И.Е.Чазовой, Т.В.Мартынюк. М.: Практика, 2015. 2. Легочная гипертензия. Российские клинические рекомендации, 2016. http://cr.rosminzdrav.ru/ schema.html?id=136#/text
2. Galiè N, Simonneau G. (eds). Updates in Pulmonary Hypertension Proceedings of the 5th World Symposium on Pulmonary Hypertension. J Am Coll Cardiol 2013; 62 (25; Suppl. D).
3. Galiè N, Humbert M, Vachiery J.L et al. 2015ESC/ERSGuidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37 (1).
4. Galiè N, Humbert M, Vachiery J.L и соавт. Рекомендации ESC/ERS по диагностике и лечению легочной гипертензии. Рос. кардиол. журн. 2016; 5 (133): 5-64. / Galiè N, Humbert M, Vachiery JL i soavt. Rekomendatsii ESC/ERS po diagnostike i lecheniiu legochnoi gipertenzii. Ros. kardiol. zhurn. 2016; 5 (133): 5-64. [in Russian]
5. Hoeper M.M, Simonneau G, Corris P.A et al. RESPITE: switching to riociguat in pulmonaryarterialhypertensionpatients with inadequateresponse to phosphodiesterase-5inhibitors. Eur Respir J 2017; 50 (3): 1602425.
6. Madigan M, Zuckerbraun B. Therapeutic Potential of the Nitrite-Generated NO Pathway in Vascular Dysfunction. Front Immunol 2013; 4: 174.
7. Wilkins M.R. Pulmonary hypertension: the science behind the disease spectrum. Eur Respir Rev 2012; 21 (123): 19-26.
8. O’Callaghan D.S, Savale L, Montari D et al. Treatment of pulmonary arterial hypertension with targeted therapies. Nat Rev Cardiol 2011; 8: 526-38.
9. Ghofrani H.A., Voswinckel R, Gall H et al. Riociguat for pulmonary hypertension. Future Cardiol 2010; 6: 155-66.
10. Stasch J.P, Pacher P, Evgenov O.V. Solubleguanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 2011; 123: 2263-73.
11. Ignarro L.J. NO More Heart Disease: How Nitric Oxide Can Prevent - Even Reverse - Heart Disease and Strokes. New York: St. Martin's Press; 2005.
12. Lundberg J.O, Gladwin M.T, Weitzberg E. Strategies to increasenitric oxidesignalling in cardiovascular disease. Nat Rev Drug Discov 2015; 14 (9): 623-41.
13. cGMP: Generators, Effectors and Therapeutic Implications. Ed. by: HH Schmidt, F Hofmann, JP Stasch. Handbook of Experimental Pharmacology 191. Springer-Verlag Berlin Heidelberg, 2009.
14. Stasch J.P, Evgenov O.V. Soluble Guanylate Cyclase Stimulators in Pulmonary Hypertension. In: Humbert et al. (eds.). Pharmacotherapy of Pulmonary Hypertension. Springer-Verlag Berlin Heidelberg, 2013; p. 279-313.
15. Cooper C.J, Landzberg M.J, Anderson T.J et al. Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans. Circulation 1996; 93: 266 -71.
16. Koshland D.E. The Molecule of the Year. Science 1992; 258: 1861.
17. Kielstein J.T, Bode-Böger S.M, Hesse G et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2005; 25 (7): 1414-8.
18. Giaid A, Saleh D. Reducedexpression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333 (4): 214-21.
19. Hemnes A.R, Champion H.C. Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension. Exp Rev Cardiovasc Ther 2006; 4: 293-300.
20. Ревацио®. Инструкция по применению лекарственного препарата для медицинского применения. ЛП-000197-13052014. http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid= 59d051ad-f651-452e-acbd-aaae0b671b74&t=96e8cd08-f9fc-4471-a60b-303dc92f2b5a]
21. Galiè N, Ghofrani H.A, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. New Engl J Med 2005; 353: 2148-2157.
22. Simonneau G, Rubin L.J, Galiè N al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension:a randomized trial. Ann Intern Med 2008; 149: 521-30.
23. Sastry B.K, Narasimhan C, Reddy N.K, Raju B.S. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004; 43 (7): 1149-53.
24. Singh T.P, Rohit M, Grover A et al. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oralsildenafiltherapy in severepulmonary artery hypertension. Am Heart J 2006; 151 (4): 851.e1-5.
25. Guha M. First-in-class guanylate cyclase stimulator approved for PAH. Nat Biotechnol 2013; 31: 1064.
26. Pulido T, Adzerikho I, Channick R.N et al. Macitentan and morbidity and mortalityin pulmonary arterial hypertension. N Engl J Med 2013; 369: 809-18.
27. Evgenov O.V, Pacher P, Schmidt P.M et al. NO-independentstimulators and activators of soluble guanylate cyclase: discovery and therapeuticpotential. Nat Rev Drug Discov 2006; 5 (9): 755-68.
28. Mittendorf J, Weigand S, Alonso-Alija C et al. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. Chem Med Chem 2009; 4: 853-65.
29. Ghofrani H.A, Galiè N, Grimminger F, Grünig E et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369: 330-40.
30. Таран И.Н., Мартынюк Т.В., Наконечников С.Н., Чазова И.Е. Инновация в медикаментозном лечении легочной артериальной гипертензии: стимулятор растворимой гуанилатциклазы - риоцигуат. Евразийский кардиол. журн. 2015; 4: 12-9.
31. Адемпас. Инструкция по применению лекарственного препарата для медицинского применения. ЛП-002639-250914. http://grls.rosminzdrav.ru/ImgInstr.aspx?folder=ScanVavilova&Filepath= Vneseno_v_Grls441575IP&idReg=86125&isOld=1&fileType=jpg&pfolder=2.
32. Rubin L.J, Galiè N, Grimminger F et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J 2015; 45: 1303-13.
33. Galiè N, Muller K, Scalise A.V, Grunig E. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in PAH. Eur Respir J 2015; 45: 1314-22.
34. Bayer A.G. Adempas (riociguat tablets): EU summary of product characteristics. www.ema.europa.eu/docs/en_GB/ document_library/EPAR_-_Product_Information/human/ 002737/WC500165034.pdf Date last updated: March 27, 2014. Accessed: 2017.
35. Bayer A.G. Adempas: US prescribing information. http://labeling.bayerhealthcare.com/html/products/pi/Adempas_ PI.pdf Date last updated: February 23, 2014. Accessed: 2017.
36. REPLACE. Riociguat replacing PDE-5i therapy evaluated against continued PDE-5i therapy. Сlinical Trials.gov Identifier: NCT02891850.
37. Taichman D.B, Ornelas J, Chung L et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest 2014; 146 (2): 449-75.
38. Politi M, Caruso N, Lescano J et al. Switch from bosentan to macitentan in adult outpatients with pulmonary arterial hypertension: a real-world study. J Heart Lung Transplant 2017; 36: 4 (Suppl.): S166.
39. Blok I.M, van Riel A.C.M.J, van Dijk A.P.J et al. From bosentan to macitentan for pulmonary arterial hypertension and adult congenital heart disease: Further improvement? Int J Cardiol 2017; 227: 51-2.
40. Safdar Z, Thakur A, Frost A. Tolerability of switch to macitentan from bosentan in pulmonary arterial hypertension. South Med J 2017; 110: 223-8.
41. Sitbon O, Manes A, Jais X et al. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension. J Cardiovasc Pharmacol 2007; 49: 1-5.
42. Coons J.C, Miller T, Simon M.A et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients transitioned from parenteral or inhaled prostacyclins: case series and treatment protocol. Pulm Circ 2016; 6: 132-5.
43. Lichtblau M, Harzheim D, Ehlken N et al. Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension. Lung 2015; 193: 105-12.
44. Dos Santos Fernandes C.J.C, Humbert M, Souza R. Challenging the concept of adding more drugs in pulmonary arterial hypertension. Eur Respir J 2017; 50: 1701527 https://doi.org/10.1183/ 13993003.01527-2017.
Рецензия
Для цитирования:
Шмальц А.А., Горбачевский С.В. Биохимический путь оксида азота в терапии легочной артериальной гипертензии и результаты исследования RESPITE. Системные гипертензии. 2018;15(2):72-76. https://doi.org/10.26442/2075-082X_2018.2.72-76
For citation:
Shmalts A.A., Gorbachevsky S.V. Nitrogen oxide biochemical pathway in pulmonary arterial hypertension therapy and REPLACE trial results. Systemic Hypertension. 2018;15(2):72-76. https://doi.org/10.26442/2075-082X_2018.2.72-76